Bone Marrow Mesenchymal Stem Cells in Acute‐on‐Chronic Liver Failure Grades 2 and 3: A Phase I‐II Randomized Clinical Trial
Canadian Journal of Gastroenterology and Hepatology · 2021-01 · 2021 (1)
DOI: 10.1155/2021/3662776 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Canadian Journal of Gastroenterology and Hepatology, online erschienen am 04.08.2021. Verfasst von Fernando Comunello Schacher und 3 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Program Sciences in Gastroenterology and Hepatology, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. Hauptthemen laut MEDLINE: Acute-On-Chronic Liver Failure, Mesenchymal Stem Cells. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Acute‐on‐chronic liver failure (ACLF) is an acute liver decompensation in cirrhotic patients, which leads to organ failures and high short‐term mortality. The treatment is based on the management of complications and, in severe cases, liver transplantation. Since specific treatment is unavailable, we aimed to evaluate the safety and initial efficacy of bone marrow mesenchymal stem cells (BM‐MSC) in patients with ACLF Grades 2 and 3, a population excluded from previous clinical trials.
Methods
This is a randomized placebo‐controlled phase I‐II single center study, which enrolled 9 cirrhotic patients from 2018 to 2020, regardless of the etiology. The control group ( n = 5) was treated with standard medical therapy (SMT) and placebo infusion of saline. The intervention group ( n = 4) received SMT plus 5 infusions of 1 × 10 6 cells/kg of BM‐MSC for 3 weeks. Both groups were monitored for 90 days. A Chi‐square test was used for qualitative variables, and the t ‐test and Mann–Whitney U test for quantitative variables. The Kaplan–Meier estimator was used to build survival curves. In this study, we followed the intention‐to‐treat analysis, with a significance of 5%.
Results
Nine patients with a mean Child–Pugh (CP) of 12.3, MELD of 38.4, and CLIF‐C score of 50.7 were recruited. Hepatitis C and alcohol were the main etiologies. The average infusion per patient was 2.9 and only 3 patients (2 in control and 1 in the BM‐MSC group) received all the protocol infusions. There were no infusion‐related side effects, although one patient in the intervention group presented hypernatremia and a gastric ulcer, after the third and fifth infusions, respectively. The survival rate after 90 days was 20% (1/5) for placebo versus 25% (1/4) for the BM‐MSC. The patient who completed the entire MSC protocol showed a significant improvement in CP (C‐14 to B‐9), MELD (32 to 22), and ACLF (grade 3 to 0).
Conclusion
BM‐MSC infusion is safe and feasible in patients with ACLF Grades 2 and 3.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Graduate Program Sciences in Gastroenterology and Hepatology, School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
- Hematology Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
- GI/Liver Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
ORCID-Profile: Fernando Comunello Schacher
Zitieren
APA
Schacher, F. C., Martins Pezzi da Silva, A., Silla, L. M. D. R., & Álvares-da-Silva, M. R. (2021). Bone Marrow Mesenchymal Stem Cells in Acute‐on‐Chronic Liver Failure Grades 2 and 3: A Phase I‐II Randomized Clinical Trial. Canadian Journal of Gastroenterology and Hepatology, 2021(1). https://doi.org/10.1155/2021/3662776
Vancouver
Schacher FC, Martins Pezzi da Silva A, Silla LMDR, Álvares-da-Silva MR. Bone Marrow Mesenchymal Stem Cells in Acute‐on‐Chronic Liver Failure Grades 2 and 3: A Phase I‐II Randomized Clinical Trial. Canadian Journal of Gastroenterology and Hepatology. 2021;2021(1). doi:10.1155/2021/3662776
BibTeX
@article{Schacher2021,
author = {Schacher, Fernando Comunello and Martins Pezzi da Silva, Annelise and Silla, Lucia Mariano da Rocha and Álvares-da-Silva, Mario Reis},
title = {Bone Marrow Mesenchymal Stem Cells in Acute‐on‐Chronic Liver Failure Grades 2 and 3: A Phase I‐II Randomized Clinical Trial},
journal = {Canadian Journal of Gastroenterology and Hepatology},
year = {2021},
volume = {2021},
number = {1},
doi = {10.1155/2021/3662776}
}
EUVIMED